Market News

Susquehanna International Group Llp Stake In National Cinemedia (Put) (NCMI) Was Has Upped; Ligand Pharmaceuticals (LGND) Share Price Rose While Tygh Capital Management Decreased by $3.93 Million Its Stake

National CineMedia, Inc. (NASDAQ:NCMI) Logo

Susquehanna International Group Llp increased its stake in National Cinemedia Inc (Put) (NCMI) by 273.99% based on its latest 2017Q4 regulatory filing with the SEC. Susquehanna International Group Llp bought 108,500 shares as the company’s stock declined 22.97% with the market. The institutional investor held 148,100 shares of the consumer services company at the end of 2017Q4, valued at $1.02M, up from 39,600 at the end of the previous reported quarter. Susquehanna International Group Llp who had been investing in National Cinemedia Inc (Put) for a number of months, seems to be bullish on the $1.14B market cap company. The stock decreased 1.80% or $0.13 during the last trading session, reaching $7.11. About 519,779 shares traded. National CineMedia, Inc. (NASDAQ:NCMI) has declined 57.75% since May 21, 2017 and is downtrending. It has underperformed by 69.30% the S&P500.

Tygh Capital Management Inc decreased its stake in Ligand Pharmaceuticals (LGND) by 37.2% based on its latest 2017Q4 regulatory filing with the SEC. Tygh Capital Management Inc sold 28,930 shares as the company’s stock rose 20.51% while stock markets declined. The institutional investor held 48,837 shares of the major pharmaceuticals company at the end of 2017Q4, valued at $6.69 million, down from 77,767 at the end of the previous reported quarter. Tygh Capital Management Inc who had been investing in Ligand Pharmaceuticals for a number of months, seems to be less bullish one the $4.15B market cap company. The stock increased 2.01% or $3.85 during the last trading session, reaching $194.99. About 1.23M shares traded or 278.14% up from the average. Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) has risen 53.11% since May 21, 2017 and is uptrending. It has outperformed by 41.56% the S&P500.

Analysts await Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) to report earnings on August, 6. They expect $0.82 earnings per share, up 51.85% or $0.28 from last year’s $0.54 per share. LGND’s profit will be $17.47M for 59.45 P/E if the $0.82 EPS becomes a reality. After $1.38 actual earnings per share reported by Ligand Pharmaceuticals Incorporated for the previous quarter, Wall Street now forecasts -40.58% negative EPS growth.

More notable recent Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) news were published by: Benzinga.com which released: “Benzinga’s Daily Biotech Pulse: Verastem Uprooted On Stock Offering, Titan Pharma Earnings” on May 16, 2018, also Streetinsider.com with their article: “Ligand Pharma (LGND) Proposed Offering of $650M of Convertible Senior Notes” published on May 16, 2018, Benzinga.com published: “Benzinga’s Daily Biotech Pulse: ASCO Abstracts, Fibrocell, Ispen And More” on May 17, 2018. More interesting news about Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) were released by: Streetinsider.com and their article: “Ligand Pharma (LGND) Tops Q1 EPS by 40c” published on May 08, 2018 as well as Globenewswire.com‘s news article titled: “New Research Coverage Highlights Assurant, Williams Partners, Atmos Energy, Nationstar Mortgage, Applied …” with publication date: May 15, 2018.

Among 6 analysts covering Ligand Pharmaceuticals (NASDAQ:LGND), 5 have Buy rating, 1 Sell and 0 Hold. Therefore 83% are positive. Ligand Pharmaceuticals had 29 analyst reports since September 3, 2015 according to SRatingsIntel. The company was maintained on Wednesday, September 30 by Roth Capital. The firm earned “Buy” rating on Friday, December 18 by Roth Capital. The firm earned “Buy” rating on Thursday, February 22 by Stephens. H.C. Wainwright maintained Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) rating on Thursday, October 5. H.C. Wainwright has “Buy” rating and $157.0 target. Roth Capital maintained it with “Buy” rating and $171.0 target in Monday, February 26 report. The rating was maintained by Deutsche Bank on Monday, July 17 with “Hold”. The rating was downgraded by Deutsche Bank on Monday, November 20 to “Sell”. The rating was maintained by Craig Hallum with “Buy” on Wednesday, March 7. On Wednesday, March 7 the stock rating was maintained by H.C. Wainwright with “Buy”. The stock of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) has “Overweight” rating given on Wednesday, April 13 by Stephens.

Investors sentiment decreased to 1.25 in 2017 Q4. Its down 0.44, from 1.69 in 2017Q3. It fall, as 21 investors sold LGND shares while 86 reduced holdings. 31 funds opened positions while 103 raised stakes. 22.68 million shares or 0.37% less from 22.76 million shares in 2017Q3 were reported. Cardinal Mngmt Limited Liability Corporation Ct reported 3.51% stake. 36,347 were reported by Citigroup Inc. Fmr Ltd Liability Company invested in 0.01% or 429,884 shares. Atlantic Tru Ltd Liability Com holds 0.09% or 146,832 shares. Us Bancorporation De accumulated 10,978 shares. Fisher Asset Limited Liability reported 0.01% in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND). Parkside Fincl Bank & Tru reported 13 shares. The Virginia-based Quantitative Inv Lc has invested 0.04% in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND). Cwm Ltd Limited Liability Company has invested 0% in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND). Prudential Incorporated stated it has 0.01% of its portfolio in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND). Wisconsin-based Convergence Invest Prtn Ltd Liability has invested 0.27% in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND). Goldman Sachs holds 221,743 shares or 0.01% of its portfolio. Gamco Invsts Et Al invested in 0.01% or 6,000 shares. Howe Rusling has invested 0.03% in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND). Strs Ohio holds 0% or 1,700 shares in its portfolio.

Tygh Capital Management Inc, which manages about $521.11 million and $531.44 million US Long portfolio, upped its stake in Charles River Laboratories (NYSE:CRL) by 28,249 shares to 64,356 shares, valued at $7.04 million in 2017Q4, according to the filing. It also increased its holding in Zayo Group Holdings Inc (NYSE:ZAYO) by 80,622 shares in the quarter, for a total of 190,102 shares, and has risen its stake in Littelfuse Inc (NASDAQ:LFUS).

Since December 20, 2017, it had 0 insider purchases, and 14 sales for $20.00 million activity. $3.71 million worth of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) was sold by HIGGINS JOHN L on Wednesday, January 24. 925 Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) shares with value of $126,956 were sold by Sabba Stephen L. Another trade for 5,444 shares valued at $832,824 was sold by FOEHR MATTHEW W. The insider Aryeh Jason sold $529,635. 3,335 shares were sold by LAMATTINA JOHN L, worth $536,604. $2.62 million worth of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) was sold by Davis Todd C on Monday, February 26.

Among 12 analysts covering National CineMedia Inc (NASDAQ:NCMI), 5 have Buy rating, 1 Sell and 6 Hold. Therefore 42% are positive. National CineMedia Inc had 29 analyst reports since August 7, 2015 according to SRatingsIntel. Benchmark maintained the stock with “Buy” rating in Tuesday, November 8 report. B. Riley & Co downgraded the stock to “Neutral” rating in Tuesday, November 7 report. The rating was downgraded by FBR Capital to “Market Perform” on Friday, May 5. The firm has “Hold” rating by FBR Capital given on Monday, January 29. Benchmark maintained National CineMedia, Inc. (NASDAQ:NCMI) rating on Friday, May 6. Benchmark has “Buy” rating and $18.76 target. The firm has “Buy” rating by FBR Capital given on Monday, May 7. The firm has “Buy” rating given on Tuesday, September 22 by Zacks. The stock of National CineMedia, Inc. (NASDAQ:NCMI) has “Buy” rating given on Monday, March 19 by FBR Capital. The firm earned “Buy” rating on Tuesday, August 8 by B. Riley & Co. The firm has “Underperform” rating given on Wednesday, February 1 by Credit Suisse.

Investors sentiment decreased to 1.06 in Q4 2017. Its down 0.33, from 1.39 in 2017Q3. It turned negative, as 22 investors sold NCMI shares while 32 reduced holdings. 21 funds opened positions while 36 raised stakes. 63.54 million shares or 0.96% less from 64.16 million shares in 2017Q3 were reported. Weitz Invest Mngmt Incorporated accumulated 150,000 shares. Arrowmark Colorado Ltd reported 0.67% stake. Federated Invsts Inc Pa stated it has 11,374 shares. The New York-based Teton Advsr Incorporated has invested 0.02% in National CineMedia, Inc. (NASDAQ:NCMI). Pinnacle Assoc holds 0% or 10,430 shares. Metropolitan Life Company stated it has 18,880 shares or 0% of all its holdings. Mondrian Investment Ptnrs has invested 0.14% in National CineMedia, Inc. (NASDAQ:NCMI). Millennium Ltd Company reported 0.01% of its portfolio in National CineMedia, Inc. (NASDAQ:NCMI). Invesco Limited has 0% invested in National CineMedia, Inc. (NASDAQ:NCMI). Lenox Wealth reported 29 shares stake. The New York-based Tower Cap Limited Com (Trc) has invested 0.04% in National CineMedia, Inc. (NASDAQ:NCMI). Rhumbline Advisers accumulated 66,343 shares or 0% of the stock. State Board Of Administration Of Florida Retirement invested in 44,414 shares. Tudor Corporation Et Al reported 34,923 shares. Ny State Common Retirement Fund accumulated 61,700 shares.

Susquehanna International Group Llp, which manages about $283.44 billion US Long portfolio, decreased its stake in Seabridge Gold Inc (Put) (NYSE:SA) by 95,500 shares to 186,900 shares, valued at $2.11 million in 2017Q4, according to the filing. It also reduced its holding in Canada Goose Holdings Inc (Put) by 17,400 shares in the quarter, leaving it with 93,100 shares, and cut its stake in Hcp Inc (NYSE:HCP).

National CineMedia, Inc. (NASDAQ:NCMI) Institutional Positions Chart

Leave a Reply

Your email address will not be published. Required fields are marked *